Economic assessment on the management of chronic lymphocytic leukaemia
In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors pe...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on pharmacotherapy 2005-06, Vol.6 (7), p.1179-1189 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1189 |
|---|---|
| container_issue | 7 |
| container_start_page | 1179 |
| container_title | Expert opinion on pharmacotherapy |
| container_volume | 6 |
| creator | Goor, Kim M Schaafsma, M Ronald Huijgens, Peter C van Agthoven, Michel |
| description | In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented. |
| doi_str_mv | 10.1517/14656566.6.7.1179 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67939062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67939062</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-9851ef4ca55065de16ce22ea7683d98cff99f7e2c51c71ab18d381beaacce6d73</originalsourceid><addsrcrecordid>eNp9kM1u3CAUhVHVqPl9gG4qr7rz1Nc2YJRsoig_lSJl067RHXypnRqYgK1q3r6MZqIom4gFF_jOEfoY-wrVCjjIH9AKnpdYiZVcAUj1iZ2AbNtSCiE-5zm_lzvgmJ2m9FxVdaV4-4UdA1dcKgkn7O7WBB_caApMiVJy5Oci-GIeqHDo8Q_tb2xhhhh85qat2wzBbOfdTMtfJDfiOTuyOCW6OOxn7Pfd7a-bh_Lx6f7nzfVjadqqnUvVcSDbGuS8ErwnEIbqmlCKrulVZ6xVykqqDQcjAdfQ9U0Ha0I0hkQvmzP2fd-7ieFloTRrNyZD04SewpK0kKpRlagzCHvQxJBSJKs3cXQYtxoqvZOnX-VpofMhy8uZb4fyZe2of0scbGXgag-M3obo8F-IU69n3E4h2ojejEk3H_VfvosPhNM8GIykn8MSfRb3we_-A609kio</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67939062</pqid></control><display><type>article</type><title>Economic assessment on the management of chronic lymphocytic leukaemia</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Goor, Kim M ; Schaafsma, M Ronald ; Huijgens, Peter C ; van Agthoven, Michel</creator><creatorcontrib>Goor, Kim M ; Schaafsma, M Ronald ; Huijgens, Peter C ; van Agthoven, Michel</creatorcontrib><description>In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.</description><identifier>ISSN: 1465-6566</identifier><identifier>EISSN: 1744-7666</identifier><identifier>DOI: 10.1517/14656566.6.7.1179</identifier><identifier>PMID: 15957971</identifier><language>eng</language><publisher>England: Ashley Publications Ltd</publisher><subject>Algorithms ; Antibodies, Monoclonal - economics ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - economics ; Antineoplastic Agents - therapeutic use ; chlorambucil ; Chlorambucil - economics ; Chlorambucil - therapeutic use ; chronic lymphocytic leukaemia ; cost analysis ; cost of illness ; Cost-Benefit Analysis ; costs ; economic evaluation ; fludarabine ; Health Care Costs ; healthcare costs ; Hospital Costs ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - economics ; Leukemia, Lymphocytic, Chronic, B-Cell - radiotherapy ; Lymphoma, Non-Hodgkin - economics ; Lymphoma, Non-Hodgkin - therapy ; monoclonal antibodies ; Randomized Controlled Trials as Topic ; stem cell transplantation ; Stem Cell Transplantation - economics ; Vidarabine - analogs & derivatives ; Vidarabine - economics ; Vidarabine - therapeutic use</subject><ispartof>Expert opinion on pharmacotherapy, 2005-06, Vol.6 (7), p.1179-1189</ispartof><rights>Ashley Publications Ltd 2005</rights><rights>2005 Ashley Publications Ltd ISSN 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-9851ef4ca55065de16ce22ea7683d98cff99f7e2c51c71ab18d381beaacce6d73</citedby><cites>FETCH-LOGICAL-c404t-9851ef4ca55065de16ce22ea7683d98cff99f7e2c51c71ab18d381beaacce6d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/14656566.6.7.1179$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/14656566.6.7.1179$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,59646,59752,60435,60541</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15957971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goor, Kim M</creatorcontrib><creatorcontrib>Schaafsma, M Ronald</creatorcontrib><creatorcontrib>Huijgens, Peter C</creatorcontrib><creatorcontrib>van Agthoven, Michel</creatorcontrib><title>Economic assessment on the management of chronic lymphocytic leukaemia</title><title>Expert opinion on pharmacotherapy</title><addtitle>Expert Opin Pharmacother</addtitle><description>In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.</description><subject>Algorithms</subject><subject>Antibodies, Monoclonal - economics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - economics</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>chlorambucil</subject><subject>Chlorambucil - economics</subject><subject>Chlorambucil - therapeutic use</subject><subject>chronic lymphocytic leukaemia</subject><subject>cost analysis</subject><subject>cost of illness</subject><subject>Cost-Benefit Analysis</subject><subject>costs</subject><subject>economic evaluation</subject><subject>fludarabine</subject><subject>Health Care Costs</subject><subject>healthcare costs</subject><subject>Hospital Costs</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - economics</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - radiotherapy</subject><subject>Lymphoma, Non-Hodgkin - economics</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>monoclonal antibodies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>stem cell transplantation</subject><subject>Stem Cell Transplantation - economics</subject><subject>Vidarabine - analogs & derivatives</subject><subject>Vidarabine - economics</subject><subject>Vidarabine - therapeutic use</subject><issn>1465-6566</issn><issn>1744-7666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1u3CAUhVHVqPl9gG4qr7rz1Nc2YJRsoig_lSJl067RHXypnRqYgK1q3r6MZqIom4gFF_jOEfoY-wrVCjjIH9AKnpdYiZVcAUj1iZ2AbNtSCiE-5zm_lzvgmJ2m9FxVdaV4-4UdA1dcKgkn7O7WBB_caApMiVJy5Oci-GIeqHDo8Q_tb2xhhhh85qat2wzBbOfdTMtfJDfiOTuyOCW6OOxn7Pfd7a-bh_Lx6f7nzfVjadqqnUvVcSDbGuS8ErwnEIbqmlCKrulVZ6xVykqqDQcjAdfQ9U0Ha0I0hkQvmzP2fd-7ieFloTRrNyZD04SewpK0kKpRlagzCHvQxJBSJKs3cXQYtxoqvZOnX-VpofMhy8uZb4fyZe2of0scbGXgag-M3obo8F-IU69n3E4h2ojejEk3H_VfvosPhNM8GIykn8MSfRb3we_-A609kio</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>Goor, Kim M</creator><creator>Schaafsma, M Ronald</creator><creator>Huijgens, Peter C</creator><creator>van Agthoven, Michel</creator><general>Ashley Publications Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050601</creationdate><title>Economic assessment on the management of chronic lymphocytic leukaemia</title><author>Goor, Kim M ; Schaafsma, M Ronald ; Huijgens, Peter C ; van Agthoven, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-9851ef4ca55065de16ce22ea7683d98cff99f7e2c51c71ab18d381beaacce6d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Algorithms</topic><topic>Antibodies, Monoclonal - economics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - economics</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>chlorambucil</topic><topic>Chlorambucil - economics</topic><topic>Chlorambucil - therapeutic use</topic><topic>chronic lymphocytic leukaemia</topic><topic>cost analysis</topic><topic>cost of illness</topic><topic>Cost-Benefit Analysis</topic><topic>costs</topic><topic>economic evaluation</topic><topic>fludarabine</topic><topic>Health Care Costs</topic><topic>healthcare costs</topic><topic>Hospital Costs</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - economics</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - radiotherapy</topic><topic>Lymphoma, Non-Hodgkin - economics</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>monoclonal antibodies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>stem cell transplantation</topic><topic>Stem Cell Transplantation - economics</topic><topic>Vidarabine - analogs & derivatives</topic><topic>Vidarabine - economics</topic><topic>Vidarabine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goor, Kim M</creatorcontrib><creatorcontrib>Schaafsma, M Ronald</creatorcontrib><creatorcontrib>Huijgens, Peter C</creatorcontrib><creatorcontrib>van Agthoven, Michel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goor, Kim M</au><au>Schaafsma, M Ronald</au><au>Huijgens, Peter C</au><au>van Agthoven, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic assessment on the management of chronic lymphocytic leukaemia</atitle><jtitle>Expert opinion on pharmacotherapy</jtitle><addtitle>Expert Opin Pharmacother</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>6</volume><issue>7</issue><spage>1179</spage><epage>1189</epage><pages>1179-1189</pages><issn>1465-6566</issn><eissn>1744-7666</eissn><abstract>In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.</abstract><cop>England</cop><pub>Ashley Publications Ltd</pub><pmid>15957971</pmid><doi>10.1517/14656566.6.7.1179</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-6566 |
| ispartof | Expert opinion on pharmacotherapy, 2005-06, Vol.6 (7), p.1179-1189 |
| issn | 1465-6566 1744-7666 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67939062 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Algorithms Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use chlorambucil Chlorambucil - economics Chlorambucil - therapeutic use chronic lymphocytic leukaemia cost analysis cost of illness Cost-Benefit Analysis costs economic evaluation fludarabine Health Care Costs healthcare costs Hospital Costs Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - economics Leukemia, Lymphocytic, Chronic, B-Cell - radiotherapy Lymphoma, Non-Hodgkin - economics Lymphoma, Non-Hodgkin - therapy monoclonal antibodies Randomized Controlled Trials as Topic stem cell transplantation Stem Cell Transplantation - economics Vidarabine - analogs & derivatives Vidarabine - economics Vidarabine - therapeutic use |
| title | Economic assessment on the management of chronic lymphocytic leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A54%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20assessment%20on%20the%20management%20of%20chronic%20lymphocytic%20leukaemia&rft.jtitle=Expert%20opinion%20on%20pharmacotherapy&rft.au=Goor,%20Kim%20M&rft.date=2005-06-01&rft.volume=6&rft.issue=7&rft.spage=1179&rft.epage=1189&rft.pages=1179-1189&rft.issn=1465-6566&rft.eissn=1744-7666&rft_id=info:doi/10.1517/14656566.6.7.1179&rft_dat=%3Cproquest_pubme%3E67939062%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67939062&rft_id=info:pmid/15957971&rfr_iscdi=true |